Gene silencing in the therapy of influenza and other respiratory diseases: Targeting to RNase P by use of external guide sequences (EGS)

Biologics: Targets and Therapy

Volumn 1, Issue 4, 2007, Pages 425-432

  Dreyfus, David H ^a,b   Tompkins, S Mark ^c   Fuleihan, Ramsay ^a   Ghoda, Lucy Y ^b,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Keren Pharmaceutical   (United States)

^c UNIVERSITY OF GEORGIA   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 83355174356     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Akira S. 2006. TLR signaling. Curr Top Microbiol Immunol, 311:1-16.
2. Baer MF, Reilly RM, Mccorkle GM, et al. 1988. The recognition by RNase P of precursor tRNAs. J Biol Chem, 263:2344-51.
3. Barnor JS, Endo Y, Habu Y, et al. 2004. Effective inhibition of HIV-1 replication in cultured cells by external guide sequences and ribonucle-ase P. Bioorg Med Chem Lett, 14:4941-4.
4. Barth H, Liang TJ, Baumert TF. 2006. Hepatitis C virus entry: molecular biology and clinical implications. Hepatology, 44:527-35.
5. Barth H, Schnober EK, Zhang F, et al. 2006. Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction. J Virol, 80:10579-90.
6. Bartkiewicz M, Gold H, Altman S. 1989. Identification and characterization of an RNA molecule that copurifies with RNase P activity from HeLa cells. Genes Dev, 3:488-99.
7. Bernstein E, Caudy AA, Hammond SM, et al. 2001. Role for a biden-tate ribonuclease in the initiation step of RNA interference. Nature, 409:363-6.
8. Bradley SP, Rastellini C, Da Costa MA, et al. 2005. Gene silencing in the endocrine pancreas mediated by short-interfering RNA. Pancreas, 31:373-9.
9. Bridge AJ, Pebernard S, Ducraux A, et al. 2003. Induction of an inter-feron response by RNAi vectors in mammalian cells. Nat Genet, 34:263-4.
10. Chan JH, Lim S, Wong WS. 2006. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol, 33:533-40.
11. Doersen CJ, Guerrier-Takada C, Altman S, et al. 1985. Characterization of an RNase P activity from HeLa cell mitochondria. Comparison with the cytosol RNase P activity. J Biol Chem, 260:5942-9.
12. Dreyfus DH, Matczuk A, Fuleihan R. 2004. An RNA external guide sequence ribozyme targeting human interleukin-4 receptor alpha mRNA. Int Immunopharmacol, 4:1015-27.
13. Elliott J, Lynch OT, Suessmuth Y, et al. 2007. Respiratory syncytial virus NS1 protein degrades STAT2 by using the Elongin-Cullin E3 ligase. J Virol, 81:3428-36.
14. Endo Y, Miyano-Kurosaki N, Kitano M, et al. 2001. Effective inhibition of HIV-1 replication in cultured cells by external guide sequences and ribonuclease. Nucleic Acids Res Suppl, 213-14.
15. Fauci AS. 1996. Host factors and the pathogenesis of HIV-induced disease. Nature, 384:529-34.
16. Fauci AS, Challberg MD. 2005. Host-based antipoxvirus therapeutic strategies: turning the tables. J Clin Invest, 115:231-3.
17. Finotto S, Buerke M, Lingnau K, et al. 2001. Local administration of antisense phosphorothioate oligonucleotides to the c-kit ligand, stem cell factor, suppresses airway inflammation and IL-4 production in a murine model of asthma. J Allergy Clin Immunol, 107:279-86.
18. Finotto S, De Sanctis GT, Lehr HA, et al. 2001. Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression. J Exp Med, 193:1247-60.
19. Georas SN, Cumberland JE, Burke TF, et al. 1998. Stat6 inhibits human interleukin-4 promoter activity in T cells. Blood, 92:4529-38.
20. Gopalan V, Vioque A, Altman S. 2002. RNase P: variations and uses. J Biol Chem, 277:6759-62.
21. Gu W, Ogose A, Kawashima H, et al. 2004. High-level expression of the coxsackievirus and adenovirus receptor messenger RNA in osteosarcoma, Ewing's sarcoma, and benign neurogenic tumors among musculoskeletal tumors. Clin Cancer Res, 10:3831-8.
22. Guerrier-Takada C, Altman S. 2000. Inactivation of gene expression using ribonuclease P and external guide sequences. Methods Enzymol, 313:442-56.
23. Guerrier-Takada C, Lumelsky N, Altman S. 1989. Specific interactions in RNA enzyme-substrate complexes. Science, 246:1578-84.
24. Guerrier-Takada C, Van Belkum A, Pleij CW, et al. 1988. Novel reactions of RNAase P with a tRNA-like structure in turnip yellow mosaic virus RNA. Cell, 53:267-72.
25. Herweijer H, Wolff JA. 2007. Gene therapy progress and prospects: hydro-dynamic gene delivery. Gene Ther, 14:99-107.
26. Hnatyszyn H, Spruill G, Young A, et al. 2001. Long-term RNase P-mediated inhibition of HIV-1 replication and pathogenesis. Gene Ther, 8:1863-71.
27. Jackson AL, Bartz SR, Schelter J, et al. 2003. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol, 21:635-7.
28. Jackson AL, Linsley PS. 2004. Noise amidst the silence: off-target effects of siRNAs? Trends Genet, 20:521-4.
29. Julg B, Goebel FD. 2005. CCR5 antagonists: a new tool in fighting HIV. J HIV Ther, 10:68-71.
30. Kariko K, Bhuyan P, Capodici J, et al. 2004. Exogenous siRNA mediates sequence-independent gene suppression by signaling through toll-like receptor 3. Cells Tissues Organs, 177:132-8.
31. Kariko K, Ni H, Capodici J, et al. 2004. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem, 279:12542-50.
32. Kitano M, Miyano-Kurosaki N, Endo Y, et al. 2000. Effective suppression of HIV-1 gene expression by a mammalian tRNA 3′ processing endoribonuclease and external guide sequence oligozymes. Nucleic Acids Symp Ser, 207-8.
33. Koller E, Propp S, Murray H, et al. 2006. Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res, 34:4467-76.
34. Kong X, Zhang W, Lockey RF, et al. 2007. Respiratory syncytial virus infection in Fischer 344 rats is attenuated by short interfering RNA against the RSV-NS1 gene. Genet Vaccines Ther, 5:4.
35. Koski RA, Bothwell AL, Altman S. 1976. Identification of a ribonuclease P-like activity from human KB cells. Cell, 9:101-16.
36. Kovrigina E, Wesolowski D, Altman S. 2003. Coordinate inhibition of expression of several genes for protein subunits of human nuclear RNase P. Proc Natl Acad Sci USA, 100:1598-602.
37. Kovrigina E, Yang L, Pfund E, et al. 2005. Regulated expression of functional external guide sequences in mammalian cells using a U6 RNA polymerase III promoter. RNA, 11:1588-95.
38. Kraus G, Geffin R, Spruill G, et al. 2002. Cross-clade inhibition of HIV-1 replication and cytopathology by using RNase P-associated external guide sequences. Proc Natl Acad Sci USA, 99:3406-11.
39. Larson SD, Jackson LN, Chen LA, et al. 2007. Effectiveness of siRNA uptake in target tissues by various delivery methods. Surgery, 142:262-9.
40. Lederman MM, Penn-Nicholson A, Cho M, et al. 2006. Biology of CCR5 and its role in HIV infection and treatment. JAMA, 296:815-26.
41. Li H, Trang P, Kim K, et al. 2006. Effective inhibition of human cytomegalovirus gene expression and growth by intracellular expression of external guide sequence RNA. RNA, 12:63-72.
42. Li HW, Ding SW. 2005. Antiviral silencing in animals. FEBS Let579:5965-73.
43. Lima WF, Monia BP, Ecker DJ, et al. 1992. Implication of RNA structure on antisense oligonucleotide hybridization kinetics. Biochemistry, 31:12055-61.
44. Liu L, Xu Z, Fuhlbrigge RC, et al. 2005. Vaccinia virus induces strong immunoregulatory cytokine production in healthy human epider-mal keratinocytes: a novel strategy for immune evasion. J Virol, 79:7363-70.
45. Ma M, Benimetskaya L, Lebedeva I, et al. 2000. Intracellular mRNA cleavage induced through activation of RNase P by nuclease-resistant external guide sequences. Nat Biotechnol, 18:58-61.
46. Ma MY, Jacob-Samuel B, Dignam JC, et al. 1998. Nuclease-resistant external guide sequence-induced cleavage of target RNA by human ribonuclease P. Antisense Nucleic Acid Drug Dev, 8:415-26.
47. Massaro D, Massaro GD, Clerch LB. 2004. Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice. Am J Physiol Lung Cell Mol Physiol, 287:L1066-70.
48. Matsukura S, Kokubu F, Kurokawa M, et al. 2006. Synthetic double-stranded RNA induces multiple genes related to inflammation through Toll-like receptor 3 depending on NF-kappaB and/or IRF-3 in airway epithelial cells. Clin Exp Allergy, 36:1049-62.
49. Minor TE, Dick EC, Baker JW, et al. 1976. Rhinovirus and influenza type A infections as precipitants of asthma. Am Rev Respir Dis, 113:149-53.
50. Monia BP, Johnston JF, Sasmor H, et al. 1996. Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras. J Biol Chem, 271:14533-40.
51. Monia BP, Lesnik EA, Gonzalez C, et al. 1993. Evaluation of 2-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expression. J Biol Chem, 268:14514-22.
52. Moschos SA, Williams AE, Lindsay MA. 2007. Cell-penetrating-peptide-mediated siRNA lung delivery. Biochem Soc Trans, 35:807-10.
53. Nyce JW. 1997. Respirable antisense oligonucleotides as novel therapeutic agents for asthma and other pulmonary diseases. Expert Opin Investig Drugs, 6:1149-56.
54. Nyce JW, Metzger WJ. 1997. DNA antisense therapy for asthma in an animal model. Nature, 385:721-5.
55. Oh JW, Lee HB, Park IK, et al. 2002. Interleukin-6, interleukin-8, interleukin-11, and interferon-gamma levels in nasopharyngeal aspirates from wheezing children with respiratory syncytial virus or influenza A virus infection. Pediatr Allergy Immunol, 13:350-6.
56. Phipps KM, Martinez A, Lu J, et al. 2004. Small interfering RNA molecules as potential anti-human rhinovirus agents: in vitro potency, specificity, and mechanism. Antiviral Res, 61:49-55.
57. Plehn-Dujowich D, Altman S. 1998. Effective inhibition of influenza virus production in cultured cells by external guide sequences and ribonucle-ase P. Proc Natl Acad Sci USA, 95:7327-32.
58. Popescu FD. 2005. Antisenseand RNA interference-based therapeutic strategies in allergy. J Cell Mol Med, 9:840-53.
59. Raj SM, Liu F. 2003. Engineering of RNase P ribozyme for gene-targeting applications. Gene, 313:59-69.
60. Rangarajan S, Raj ML, Hernandez JM, et al. 2004. RNase P as a tool for disruption of gene expression in maize cells. Biochem J, 380:611-6.
61. Robb GB, Rana TM. 2007. RNA helicase A interacts with RISC in human cells and functions in RISC loading. Mol Cell, 26:523-37.
62. Robertson HD, Altman S, Smith JD. 1972. Purification and properties of a specific Escherichia coli ribonuclease which cleaves a tyrosine transfer ribonucleic acid presursor. J Biol Chem, 247:5243-51.
63. Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, et al. 2004. Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci USA, 101:1892-7.
64. Schott DH, Cureton DK, Whelan SP, et al. 2005. An antiviral role for the RNA interference machinery in Caenorhabditis elegans. Proc Natl Acad Sci USA, 102:18420-4.
65. Schutz S, Sarnow P. 2006. Interaction of viruses with the mammalian RNA interference pathway. Virology, 344:151-7.
66. Singh AM, Busse WW. 2006. Asthma exacerbations. 2: aetiology. Thorax, 61:809-16.
67. Strayer DS, Feitelson M, Sun B, et al. 2005. Paradigms for conditional expression of RNA interference molecules for use against viral targets. Methods Enzymol, 392:227-41.
68. Tekkanat KK, Maassab HF, Cho DS, et al. 2001. IL-13-induced airway hyperreactivity during respiratory syncytial virus infection is STAT6 dependent. J Immunol, 166:3542-8.
69. Thomas M, Lu JJ, Chen J, et al. 2007. Non-viral siRNA delivery to the lung. Adv Drug Deliv Rev, 59:124-33.
70. Tompkins SM, Lo CY, Tumpey TM, et al. 2004. Protection against lethal influenza virus challenge by RNA interference in vivo. Proc Natl Acad Sci USA, 101:8682-6.
71. Trian T, Girodet PO, Ousova O, et al. 2006. RNA interference decreases PAR-2 expression and function in human airway smooth muscle cells. Am J Respir Cell Mol Biol, 34:49-55.
72. Ulanova M, Schreiber AD, Befus AD. 2006. The future of antisense oligonucleotides in the treatment of respiratory diseases. BioDrugs, 20:1-11.
73. Wang SZ, Bao YX, Rosenberger CL, et al. 2004. IL-12p40 and IL-18 modulate inflammatory and immune responses to respiratory syncytial virus infection. J Immunol, 173:4040-9.
74. Weber J, Piontkivska H, Quinones-Mateu ME. 2006. HIV type 1 tropism and inhibitors of viral entry: clinical implications. AIDS Rev, 8:60-77.
75. Yang L, Wesolowski D, Li Y, et al. 2005. Analysis of putative RNase PRNA from orthopoxviruses. J Mol Biol, 354:529-35.
76. Yang YH, Li H, Zhou T, et al. 2006. Engineered external guide sequences are highly effective in inducing RNase P for inhibition of gene expression and replication of human cytomegalovirus. Nucleic Acids Res, 34:575-83.
77. Yasuda H, Suzuki T, Zayasu K, et al. 2005. Inflammatory and bronchospastic factors in asthma exacerbations caused by upper respiratory tract infections. Tohoku J Exp Med, 207:109-18.
78. Zhang H, Altman S. 2004. Inhibition of the expression of the human RNase P protein subunits Rpp21, Rpp25, Rpp29 by external guide sequences (EGSs) and siRNA. J Mol Biol, 342:1077-83.
79. Zhou T, Kim J, Kilani AF, et al. 2002. In vitro selection of external guide sequences for directing RNase P-mediated inhibition of viral gene expression. J Biol Chem, 277:30112-20.
80. Zhu J, Trang P, Kim K, et al. 2004. Effective inhibition of Rta expression and lytic replication of Kaposi's sarcoma-associated herpesvirus by human RNase P. Proc Natl Acad Sci USA, 101:9073-8.
81. Ziehler WA, Day JJ, Fierke CA, et al. 2000. Effects of 5′ leader and 3′ trailer structures on pre-tRNA processing by nuclear RNase P. Biochemistry, 39:9909-16.